Beta Bionics, Inc. Financials
This page shows Beta Bionics, Inc. (BBNX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Beta Bionics, Inc. has an operating margin of -71.5%, meaning the company retains $-72 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -69.5% the prior year.
Beta Bionics, Inc.'s revenue surged 53.9% year-over-year to $100.3M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Beta Bionics, Inc. carries a low D/E ratio of 0.14, meaning only $0.14 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 8.66, Beta Bionics, Inc. holds $8.66 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Beta Bionics, Inc. generated -$50.9M in operating cash flow, capex of $5.3M consumed most of it, leaving -$56.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Beta Bionics, Inc. generates a -25.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
Beta Bionics, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Beta Bionics, Inc. generates $0.70 in operating cash flow (-$50.9M OCF vs -$73.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Beta Bionics, Inc. generated $100.3M in revenue in fiscal year 2025. This represents an increase of 53.9% from the prior year.
Beta Bionics, Inc.'s EBITDA was -$70.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 59.0% from the prior year.
Beta Bionics, Inc. reported -$73.2M in net income in fiscal year 2025. This represents a decrease of 33.7% from the prior year.
Beta Bionics, Inc. earned $-1.81 per diluted share (EPS) in fiscal year 2025. This represents an increase of 79.0% from the prior year.
Cash & Balance Sheet
Beta Bionics, Inc. generated -$56.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 8.8% from the prior year.
Beta Bionics, Inc. held $31.6M in cash against $0 in long-term debt as of fiscal year 2025.
Beta Bionics, Inc. had 44M shares outstanding in fiscal year 2025. This represents an increase of 565.3% from the prior year.
Margins & Returns
Beta Bionics, Inc.'s gross margin was 55.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.3 percentage points from the prior year.
Beta Bionics, Inc.'s operating margin was -71.5% in fiscal year 2025, reflecting core business profitability. This is down 2.0 percentage points from the prior year.
Beta Bionics, Inc.'s net profit margin was -73.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 11.1 percentage points from the prior year.
Beta Bionics, Inc.'s ROE was -25.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Beta Bionics, Inc. invested $34.8M in research and development in fiscal year 2025. This represents an increase of 32.9% from the prior year.
Beta Bionics, Inc. invested $5.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 56.0% from the prior year.
BBNX Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $32.1M+17.9% | $27.3M+17.3% | $23.2M+31.7% | $17.6M-13.7% | $20.4M+22.4% | $16.7M+11.0% | $15.0M+16.3% | $12.9M |
| Cost of Revenue | $13.2M+8.6% | $12.1M+13.0% | $10.7M+23.8% | $8.7M-0.9% | $8.8M+12.3% | $7.8M+11.9% | $7.0M+21.5% | $5.7M |
| Gross Profit | $18.9M+25.3% | $15.1M+20.9% | $12.5M+39.4% | $9.0M-23.3% | $11.7M+31.1% | $8.9M+10.3% | $8.1M+12.3% | $7.2M |
| R&D Expenses | $10.1M+23.6% | $8.2M-7.6% | $8.9M+16.9% | $7.6M-17.6% | $9.2M+79.2% | $5.1M-19.0% | $6.3M+15.9% | $5.5M |
| SG&A Expenses | $8.6M+8.6% | $7.9M+0.5% | $7.9M+19.0% | $6.6M+40.6% | $4.7M-7.8% | $5.1M+12.3% | $4.5M+29.4% | $3.5M |
| Operating Income | -$16.1M+5.4% | -$17.0M+14.2% | -$19.9M-6.6% | -$18.6M-43.0% | -$13.0M-18.8% | -$11.0M+6.8% | -$11.8M-24.7% | -$9.5M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$13.5M+5.2% | -$14.2M+15.8% | -$16.9M+41.1% | -$28.7M-58.3% | -$18.1M-86.0% | -$9.7M+32.7% | -$14.5M-16.2% | -$12.4M |
| EPS (Diluted) | N/A | $-0.33+15.4% | $-0.39+58.1% | $-0.93 | N/A | $-1.46+38.4% | $-2.37-14.5% | $-2.07 |
BBNX Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $328.7M-0.4% | $330.0M0.0% | $330.0M-2.4% | $338.0M+125.9% | $149.6M | N/A | N/A | N/A |
| Current Assets | $267.9M-0.8% | $270.0M-5.6% | $286.1M+9.2% | $261.9M+97.0% | $132.9M | N/A | N/A | N/A |
| Cash & Equivalents | $31.6M-18.0% | $38.5M+9.7% | $35.1M-17.4% | $42.5M+39.5% | $30.4M+74.1% | $17.5M+34.2% | $13.0M-41.0% | $22.1M |
| Inventory | $21.7M+6.6% | $20.4M+17.6% | $17.3M+10.1% | $15.7M+18.1% | $13.3M | N/A | N/A | N/A |
| Accounts Receivable | $17.1M+48.3% | $11.5M+1.3% | $11.4M+25.8% | $9.1M-24.5% | $12.0M | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $41.1M+16.6% | $35.3M+24.5% | $28.3M+16.8% | $24.3M-93.9% | $395.0M | N/A | N/A | N/A |
| Current Liabilities | $30.9M+21.8% | $25.4M+30.3% | $19.5M+18.2% | $16.5M-22.0% | $21.1M | N/A | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $287.6M-2.4% | $294.8M-2.3% | $301.6M-3.9% | $313.8M+227.9% | -$245.4M-7.2% | -$228.8M-3.5% | -$221.2M-3.2% | -$214.3M |
| Retained Earnings | -$369.9M-3.8% | -$356.5M-4.2% | -$342.3M-5.2% | -$325.4M-9.7% | -$296.7M | N/A | N/A | N/A |
BBNX Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.6M+1.2% | -$8.7M+35.8% | -$13.6M+31.9% | -$20.0M-39.9% | -$14.3M-48.5% | -$9.6M+21.4% | -$12.2M-0.8% | -$12.1M |
| Capital Expenditures | $1.9M+48.4% | $1.3M-27.9% | $1.8M+434.2% | $333K-40.6% | $561K-70.8% | $1.9M+278.9% | $507K+24.9% | $406K |
| Free Cash Flow | -$10.5M-5.2% | -$10.0M+34.9% | -$15.4M+24.3% | -$20.3M-36.8% | -$14.8M-28.7% | -$11.5M+9.5% | -$12.7M-1.5% | -$12.6M |
| Investing Cash Flow | $658K-93.1% | $9.5M+53.7% | $6.2M+103.4% | -$179.1M-503.9% | -$29.7M-294.6% | $15.2M+361.9% | $3.3M-56.8% | $7.6M |
| Financing Cash Flow | $1.1M-60.0% | $2.7M+6216.7% | $42K-100.0% | $211.1M+271.1% | $56.9M+4937.8% | -$1.2M-999.1% | -$107K-1883.3% | $6K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BBNX Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.0%+3.5pp | 55.5%+1.7pp | 53.8%+2.9pp | 50.9%-6.3pp | 57.2%+3.8pp | 53.4%-0.4pp | 53.7%-1.9pp | 55.7% |
| Operating Margin | -50.2%+12.3pp | -62.5%+23.0pp | -85.5%+20.2pp | -105.7%-41.9pp | -63.8%+1.9pp | -65.7%+12.6pp | -78.3%-5.2pp | -73.1% |
| Net Margin | -41.9%+10.2pp | -52.1%+20.5pp | -72.6%+89.9pp | -162.5%-73.9pp | -88.6%-30.3pp | -58.3%+37.9pp | -96.1%+0.1pp | -96.3% |
| Return on Equity | -4.7%+0.1pp | -4.8%+0.8pp | -5.6%+3.5pp | -9.1% | N/A | N/A | N/A | N/A |
| Return on Assets | -4.1%+0.2pp | -4.3%+0.8pp | -5.1%+3.4pp | -8.5%+3.6pp | -12.1% | N/A | N/A | N/A |
| Current Ratio | 8.66-2.0 | 10.64-4.0 | 14.68-1.2 | 15.88+9.6 | 6.29 | N/A | N/A | N/A |
| Debt-to-Equity | 0.14+0.0 | 0.12+0.0 | 0.09+0.0 | 0.08+1.7 | -1.61 | N/A | N/A | N/A |
| FCF Margin | -32.8%+4.0pp | -36.7%+29.4pp | -66.1%+49.0pp | -115.1%-42.5pp | -72.6%-3.5pp | -69.0%+15.6pp | -84.7%+12.3pp | -97.0% |
Similar Companies
Frequently Asked Questions
What is Beta Bionics, Inc.'s annual revenue?
Beta Bionics, Inc. (BBNX) reported $100.3M in total revenue for fiscal year 2025. This represents a 53.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Beta Bionics, Inc.'s revenue growing?
Beta Bionics, Inc. (BBNX) revenue grew by 53.9% year-over-year, from $65.1M to $100.3M in fiscal year 2025.
Is Beta Bionics, Inc. profitable?
No, Beta Bionics, Inc. (BBNX) reported a net income of -$73.2M in fiscal year 2025, with a net profit margin of -73.0%.
What is Beta Bionics, Inc.'s EBITDA?
Beta Bionics, Inc. (BBNX) had EBITDA of -$70.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Beta Bionics, Inc.'s gross margin?
Beta Bionics, Inc. (BBNX) had a gross margin of 55.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Beta Bionics, Inc.'s operating margin?
Beta Bionics, Inc. (BBNX) had an operating margin of -71.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Beta Bionics, Inc.'s net profit margin?
Beta Bionics, Inc. (BBNX) had a net profit margin of -73.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Beta Bionics, Inc.'s return on equity (ROE)?
Beta Bionics, Inc. (BBNX) has a return on equity of -25.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Beta Bionics, Inc.'s free cash flow?
Beta Bionics, Inc. (BBNX) generated -$56.2M in free cash flow during fiscal year 2025. This represents a -8.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Beta Bionics, Inc.'s operating cash flow?
Beta Bionics, Inc. (BBNX) generated -$50.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Beta Bionics, Inc.'s total assets?
Beta Bionics, Inc. (BBNX) had $328.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Beta Bionics, Inc.'s capital expenditures?
Beta Bionics, Inc. (BBNX) invested $5.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Beta Bionics, Inc. spend on research and development?
Beta Bionics, Inc. (BBNX) invested $34.8M in research and development during fiscal year 2025.
What is Beta Bionics, Inc.'s current ratio?
Beta Bionics, Inc. (BBNX) had a current ratio of 8.66 as of fiscal year 2025, which is generally considered healthy.
What is Beta Bionics, Inc.'s debt-to-equity ratio?
Beta Bionics, Inc. (BBNX) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Beta Bionics, Inc.'s return on assets (ROA)?
Beta Bionics, Inc. (BBNX) had a return on assets of -22.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Beta Bionics, Inc.'s cash runway?
Based on fiscal year 2025 data, Beta Bionics, Inc. (BBNX) had $31.6M in cash against an annual operating cash burn of $50.9M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Beta Bionics, Inc.'s Piotroski F-Score?
Beta Bionics, Inc. (BBNX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Beta Bionics, Inc.'s earnings high quality?
Beta Bionics, Inc. (BBNX) has an earnings quality ratio of 0.70x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Beta Bionics, Inc.?
Beta Bionics, Inc. (BBNX) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.